Mr. Henry Dubina reports

TELESCOPE INNOVATIONS PROVIDES FINANCIAL RESULTS OF THIRD FISCAL QUARTER 2026

Telescope Innovations Corp. has released financial results for the fiscal quarter ended May 31, 2026 (Q3 FY 2026). The company generated revenues of approximately $2.1-million during this period, driven by a combination of contract services and self-driving lab (SDL) projects, with an adjusted EBITA (earnings before interest, taxes and amortization) loss of $1.1-million. Year-to-date gross revenues increased to $6.5-million, compared with $3.6-million in the same six-month period last year, representing 80-per-cent growth. The company continues to develop and convert its SDL pipeline, with its third platform contract secured in Q3 for a major global pharmaceutical company.

Financial highlights of the fiscal quarter ended May 31, 2026 (Q3 FY 2026) (all values are represented in Canadian dollars):

• Revenues of $2.12-million (versus $1.39-million in Q3 FY 2025);
• Expenses of $3.53-million (versus $1.9-million in Q3 FY 2025);
• Adjusted EBITA loss of $1.06-million (versus a loss of $100,000 in Q3 FY 2025);
• Expenses and investments continued to support company growth in the third fiscal quarter; expense increases were associated with:
  • Consulting and salary costs incurred with hiring of technical, sales and research to support rapid growth in the business;
  • Marketing expenses to support the company's visibility and market presence for continued growth;
  • Parts, lab operations and supplies, and office expenses related to additional business activity supporting long-term technology development products, including self-driving lab projects.

Operational highlights:

• Self-driving labs (SDLs):
  • In Q3 2026, the company received a contract from a major European pharmaceutical company for Telescope's third self-driving lab. The platform is expected to be installed at the client's European facilities within the coming months.
• Automation technology for chemical reaction sampling:
  • Telescope signed a development and collaboration agreement with AGI Group's synthesis, digitization and automation division to develop new chemical reactor technology. Telescope has made significant progress in this project, leveraging market-proven expertise related to its DirectInject-LC product. DirectInject-LC technology for reliably managing reaction samples will be seamlessly integrated into the AGI reactor system, coupling automated reaction execution with real-time, hands-free analysis.
  • In Q3 2026, Telescope invoiced against a platform for analysis of minerals based on DirectInject-IC (ion chromatography), which quantitatively measures critical ions involved with the purification of high-value materials to support the lithium battery industry. This instrument is a key part of the company's road map for energy and battery materials, where precise, autonomous monitoring of trace metals is essential for process optimization.

"While we are intentionally investing in talent, infrastructure and product development to support long-term growth, we are particularly encouraged by the expansion of our SDL pipeline, including securing a third platform with a major global pharmaceutical partner," said Henry Dubina, chief executive officer of Telescope. "These milestones, and our 80-per-cent growth in year-to-date revenue compared to last year, validate our strategy to deliver intelligent automation solutions that accelerate innovation in pharmaceuticals, chemicals and emerging areas such as battery materials. We remain focused on scaling our platform and converting our growing pipeline into sustained revenue growth."

Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the quarter ended May 31, 2026, both of which are available under the profile for the company on SEDAR+.

About Telescope Innovations Corp.

Telescope is a chemical technology company developing intelligent automation technologies and scalable manufacturing processes for the pharmaceutical and chemical industry. The company builds and deploys reaction sampling systems for real-time analysis, flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency and data quality. The company's self-driving labs are fully autonomous, physical AI (artificial intelligence) platforms that plan, execute and analyze experiments far more efficiently than traditional manual approaches. Biopharmaceutical, high-value specialty chemical and advanced materials companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market.

We seek Safe Harbor.